A comparative study of valaciclovir, valganciclovir, and artesunate efficacy in reactivated HHV-6 and HHV-7 infections associated with chronic fatigue syndrome/myalgic encephalomyelitis. — CFSMEATLAS
A comparative study of valaciclovir, valganciclovir, and artesunate efficacy in reactivated HHV-6 and HHV-7 infections associated with chronic fatigue syndrome/myalgic encephalomyelitis.
Maltsev, Dmitry · Microbiology and immunology · 2022 · DOI
Quick Summary
This study tested three antiviral medications in ME/CFS patients who had reactivated herpesvirus infections (HHV-6 and HHV-7). Over three months, the drug artesunate was more effective at clearing the virus from the blood than two other antivirals (valaciclovir and valganciclovir). By the third month, artesunate cleared the virus in about 68% of HHV-6 cases and 63% of HHV-7 cases, compared to 37% and 34% with valaciclovir.
Why It Matters
Since some ME/CFS patients have evidence of herpesvirus reactivation, identifying more effective antiviral treatments could offer therapeutic options for a subset of the patient population. This study directly compares three potential treatment approaches, providing preliminary evidence that artesunate may warrant further investigation in ME/CFS-associated herpesvirus infections.
Observed Findings
By month 3, artesunate achieved 68% HHV-6 and 63% HHV-7 PCR negativity, compared to 48%/45% for valganciclovir and 37%/34% for valaciclovir
Valganciclovir showed intermediate effectiveness, outperforming valaciclovir across all three months
Viral clearance rates increased progressively over the three-month treatment period for all three drugs
The control group (untreated ME/CFS patients) data are not detailed in the abstract regarding spontaneous viral clearance rates
Inferred Conclusions
Artesunate is more effective than standard antiviral medications at achieving PCR-negative status for HHV-6 and HHV-7 in ME/CFS patients
Among the three tested antivirals, artesunate should be considered as a potential treatment option for HHV-6/HHV-7 reactivation in ME/CFS
Progressive viral clearance over three months suggests extended treatment duration may be necessary for optimal virological response
Remaining Questions
Did viral clearance correlate with clinical symptom improvement, fatigue severity, or functional capacity in any treatment group?
What were the adverse effects and tolerability profiles of these three medications, and did dropout rates differ between groups?
Why was artesunate (an antimalarial derivative) more effective than established antivirals, and what are the proposed mechanisms?
What This Study Does Not Prove
This study does not prove that HHV-6/HHV-7 reactivation causes ME/CFS or that clearing these viruses will improve ME/CFS symptoms. As an observational study without random assignment and without documented clinical outcome measures, it establishes viral clearance rates but not clinical efficacy. The lack of blinding and control group details limits conclusions about causal treatment effects.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Phenotype:Infection-Triggered
Method Flag:PEM Not DefinedWeak Case DefinitionSmall Sample
What proportion of ME/CFS patients actually have detectable HHV-6/HHV-7 reactivation, and does treatment benefit patients with vs. without viral reactivation differently?